DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,633,113 | +28.1% | 55,341 | 0.0% | 0.06% | +29.5% |
| Q1 2023 | $1,275,057 | -17.2% | 55,341 | 0.0% | 0.04% | -25.4% |
| Q4 2022 | $1,539,033 | -1.6% | 55,341 | +8.6% | 0.06% | -9.2% |
| Q3 2022 | $1,564,000 | +4.3% | 50,971 | 0.0% | 0.06% | +14.0% |
| Q2 2022 | $1,500,000 | -8.5% | 50,971 | 0.0% | 0.06% | +14.0% |
| Q1 2022 | $1,640,000 | -27.8% | 50,971 | 0.0% | 0.05% | -20.6% |
| Q4 2021 | $2,273,000 | +46.4% | 50,971 | +65.5% | 0.06% | +43.2% |
| Q3 2021 | $1,553,000 | -35.7% | 30,791 | 0.0% | 0.04% | -21.4% |
| Q2 2021 | $2,415,000 | +37.4% | 30,791 | 0.0% | 0.06% | +43.6% |
| Q1 2021 | $1,758,000 | -31.8% | 30,791 | 0.0% | 0.04% | -33.9% |
| Q4 2020 | $2,579,000 | +1.7% | 30,791 | -56.5% | 0.06% | -6.3% |
| Q3 2020 | $2,537,000 | +48.2% | 70,793 | 0.0% | 0.06% | +61.5% |
| Q2 2020 | $1,712,000 | +38.1% | 70,793 | 0.0% | 0.04% | +25.8% |
| Q1 2020 | $1,240,000 | – | 70,793 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |